2020–2021 Drug Updates in Solid Tumors

During JADPRO Live Virtual 2021, Christine Cambareri, PharmD, BCPS, BCOP, CSP, briefed advanced practitioners on drugs and biologics that were approved for the treatment of solid tumors from late 2020 to late 2021, including their adverse event profiles. The trend of more oral dosage forms and the s...

Descripción completa

Detalles Bibliográficos
Autor principal: Cambareri, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2022
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126351/
https://www.ncbi.nlm.nih.gov/pubmed/35663163
http://dx.doi.org/10.6004/jadpro.2022.13.3.19
_version_ 1784712108431114240
author Cambareri, Christine
author_facet Cambareri, Christine
author_sort Cambareri, Christine
collection PubMed
description During JADPRO Live Virtual 2021, Christine Cambareri, PharmD, BCPS, BCOP, CSP, briefed advanced practitioners on drugs and biologics that were approved for the treatment of solid tumors from late 2020 to late 2021, including their adverse event profiles. The trend of more oral dosage forms and the significant number of checkpoint inhibitors approved points towards changing treatment paradigms in the field.
format Online
Article
Text
id pubmed-9126351
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-91263512022-06-04 2020–2021 Drug Updates in Solid Tumors Cambareri, Christine J Adv Pract Oncol Meeting Reports During JADPRO Live Virtual 2021, Christine Cambareri, PharmD, BCPS, BCOP, CSP, briefed advanced practitioners on drugs and biologics that were approved for the treatment of solid tumors from late 2020 to late 2021, including their adverse event profiles. The trend of more oral dosage forms and the significant number of checkpoint inhibitors approved points towards changing treatment paradigms in the field. Harborside Press LLC 2022-04 2022-05-23 /pmc/articles/PMC9126351/ /pubmed/35663163 http://dx.doi.org/10.6004/jadpro.2022.13.3.19 Text en © 2022 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Reports
Cambareri, Christine
2020–2021 Drug Updates in Solid Tumors
title 2020–2021 Drug Updates in Solid Tumors
title_full 2020–2021 Drug Updates in Solid Tumors
title_fullStr 2020–2021 Drug Updates in Solid Tumors
title_full_unstemmed 2020–2021 Drug Updates in Solid Tumors
title_short 2020–2021 Drug Updates in Solid Tumors
title_sort 2020–2021 drug updates in solid tumors
topic Meeting Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126351/
https://www.ncbi.nlm.nih.gov/pubmed/35663163
http://dx.doi.org/10.6004/jadpro.2022.13.3.19
work_keys_str_mv AT cambarerichristine 20202021drugupdatesinsolidtumors

Ejemplares similares